Literature DB >> 20136972

Toward elimination and eradication of hepatitis B.

Ding-Shinn Chen1.   

Abstract

Hepatitis B virus (HBV) causes important human health problems. It has infected one-third of the world's population and approximately 360 million people are chronic carriers. Worldwide, 0.5-1.2 million deaths are attributed to HBV infection annually. Therefore, global control of HBV infection is important. HBV infection can be intervened by interrupting routes of transmission, treating the chronically infected, and preventing the susceptibles with immunoprophylaxis. All these measures are effective. Nevertheless, although pegylated interferons or nucleos(t)ide analogs are effective for the treatment of chronic hepatitis B, chronic carriage of HBV is not easy to eliminate, as revealed by the frequent persistence of hepatitis B surface antigen, despite satisfactory responses to these treatments. On the other hand, hepatitis B vaccination has been shown to preclude HBV infection effectively. This is particularly true for pre-exposure prophylaxis. Worthy of note is the universal vaccination of newborn infants. This is the most effective means of preventing HBV infection, especially for those born to HBV carrier mothers. To eliminate and eradicate hepatitis B, first, HBV in the chronically infected should be eradicated or strongly and efficiently suppressed, so that the infection does not spread rampantly. Second, all the transmission routes should be interrupted. Lastly, but most effectively, is to immunize all susceptibles. The difficulties and possible solutions of each approach are discussed. In conclusion, the existing means to prevent and treat HBV infection render our goal toward eliminating and eradicating hepatitis B possible, although it will take much time and effort to achieve this objective.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20136972     DOI: 10.1111/j.1440-1746.2009.06165.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  26 in total

1.  Hepatocellular carcinoma in Asia: Prevention strategy and planning.

Authors:  Sara Ashtari; Mohamad Amin Pourhoseingholi; Afsaneh Sharifian; Mohamad Reza Zali
Journal:  World J Hepatol       Date:  2015-06-28

2.  Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotype B and C HBV-infected children.

Authors:  Jia-Feng Wu; Yu-Ru Su; Chen-Hsin Chen; Huey-Ling Chen; Yen-Hsuan Ni; Hong-Yuan Hsu; Jane-Ling Wang; Mei-Hwei Chang
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-01       Impact factor: 2.839

Review 3.  Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives.

Authors:  Wolfram H Gerlich
Journal:  Med Microbiol Immunol       Date:  2014-12-19       Impact factor: 3.402

4.  A mouse model for HBV immunotolerance and immunotherapy.

Authors:  Dan Yang; Longchao Liu; Danming Zhu; Hua Peng; Lishan Su; Yang-Xin Fu; Liguo Zhang
Journal:  Cell Mol Immunol       Date:  2013-09-30       Impact factor: 11.530

5.  Hepatitis B: Epidemiology and prevention in developing countries.

Authors:  Elisabetta Franco; Barbara Bagnato; Maria Giulia Marino; Cristina Meleleo; Laura Serino; Laura Zaratti
Journal:  World J Hepatol       Date:  2012-03-27

6.  Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes.

Authors:  Jan Felix Drexler; Andreas Geipel; Alexander König; Victor M Corman; Debby van Riel; Lonneke M Leijten; Corinna M Bremer; Andrea Rasche; Veronika M Cottontail; Gael D Maganga; Mathias Schlegel; Marcel A Müller; Alexander Adam; Stefan M Klose; Aroldo José Borges Carneiro; Andreas Stöcker; Carlos Roberto Franke; Florian Gloza-Rausch; Joachim Geyer; Augustina Annan; Yaw Adu-Sarkodie; Samuel Oppong; Tabea Binger; Peter Vallo; Marco Tschapka; Rainer G Ulrich; Wolfram H Gerlich; Eric Leroy; Thijs Kuiken; Dieter Glebe; Christian Drosten
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

7.  Viral hepatitis: Indian scenario.

Authors:  Sandeep Satsangi; Yogesh K Chawla
Journal:  Med J Armed Forces India       Date:  2016-08-09

8.  Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women.

Authors:  Pai-Jong Stacy Tsai; Ann Chang; Seiji Yamada; Naoky Tsai; Marguerite Lisa Bartholomew
Journal:  Dig Dis Sci       Date:  2014-06-05       Impact factor: 3.199

Review 9.  Phage display creates innovative applications to combat hepatitis B virus.

Authors:  Wen Siang Tan; Kok Lian Ho
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

10.  Development of a sensitive enzyme-linked immunosorbent assay for detection of hepatitis B surface antigen using novel monoclonal antibodies.

Authors:  Yaghoub Yazdani; Azam Roohi; Jalal Khoshnoodi; Fazel Shokri
Journal:  Avicenna J Med Biotechnol       Date:  2010-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.